Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Pretax margin (%)

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-370.4+13.26%
Dec 31, 2024-327+372.11%
Dec 31, 2023-69.3-24.88%
Dec 31, 2022-92.2+255.74%
Dec 31, 2021-25.9-72.72%
Dec 31, 2020-95-418.47%
Dec 31, 201929.8-119.43%
Dec 31, 2018-153.6+41.95%
Dec 31, 2017-108.2+99.30%
Dec 31, 2016-54.3-273.09%
Dec 31, 201531.4-131.61%
Dec 31, 2014-99.3+176.93%
Dec 31, 2013-35.8-58.64%
Dec 31, 2012-86.7+50.92%
Dec 31, 2011-57.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat